GlassScriptPhysician profile
James B Bragman
NPI 1558352286
$9,947.93
in general payments reported to CMS, 2019-2025
35 companies · $4,860 in 2025
The $4,860 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $477 · 2021: $998 · 2022: $621 · 2023: $1,723 · 2024: $546 · 2025: $4,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,095 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,700 · Travel and Lodging: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,700.00 |
| Travel and Lodging | $1,333.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,704.62 | 2022-2025 | Watchman Access System, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $1,017.97 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $727.49 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.48 | 2020-2024 | Jardiance, Tradjenta, Glyxambi |
| Amgen INC. | $468.66 | 2019-2025 | Repatha, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.17 | 2019-2025 | Xifaxan |
| Abbvie INC. | $330.28 | 2021-2025 | Vraylar, Ubrelvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.69 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $221.21 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $180.70 | 2021 | |
| Lilly USA, LLC | $141.74 | 2020-2023 | Mounjaro, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $78.99 | 2021-2023 | Eliquis |
| Abbott Laboratories | $74.99 | 2022-2023 | Proclaim, Freestyle Libre 2 |
| Exact Sciences Corporation | $72.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $71.92 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $58.18 | 2020 | |
| Amneal Pharmaceuticals LLC | $57.69 | 2023 | Unithroid |
| Novartis Pharmaceuticals Corporation | $57.57 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.86 | 2020-2025 | Vpriv |
| Corium, LLC | $48.12 | 2022-2023 | Adlarity |
| Horizon Therapeutics Plc | $46.22 | 2021-2022 | |
| Axsome Therapeutics, INC. | $44.47 | 2022-2025 | Auvelity |
| Biogen, INC. | $44.30 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $36.80 | 2019-2021 | |
| Genzyme Corporation | $36.67 | 2021-2022 | |
| Janssen Biotech, INC. | $24.62 | 2019 | |
| Bardy Diagnostics, INC. | $22.16 | 2021 | |
| Smith+Nephew, INC. | $20.85 | 2025 | Collagenase Santyl |
| Validus Pharmaceuticals LLC | $20.00 | 2025 | Equetro |
| Genentech USA, INC. | $17.08 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $16.52 | 2024 | Opsumit, Uptravi |
| Lucid Diagnostics INC. | $14.67 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $14.24 | 2025 | Rexulti |
| Baxter Healthcare | $13.51 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Circassia INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bragman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.